Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Metadata
Provider: 
PR NewswirePR Newswire
Retrieved on: 
Monday, November 28, 2022
Information
Tags: 
Autoimmune disease, Autoimmunity, Metastasis, Environment, CML, Medicine, Nature, NSCLC, Selpercatinib, Metabolic disorder, Hospital, Chemistry, CMC, Soochow University, TKI, Eli Lilly and Company, Mutation, First Affiliated Hospital of Xinjiang Medical University, Eli Lilly, Trial of the century, Ophthalmology, Peking Union Medical College, Ramucirumab, HKEX, Control, News, Tolerability, NDA, Efficacy, Cancer, Social conditions in Honduras, Integrity, Stock exchange, Main, MD Anderson Cancer Center, Sintilimab, Bevacizumab, The First Affiliated Hospital of Wenzhou Medical University, NMPA, Motherboard, Vaccine, Management, Pharmaceutical industry, Patient, Safety, Spotlight Innovation, Hematology, Incyte
Geotags: 
CHINA, CALIFORNIA, MARYLAND, UNITED STATES, TAIWAN, MACAU, HONG KONG
⚠ generated by AI ↴
Organisation: 
INNOVENT BIOLOGICS, INNOVENT
Stock Symbol: 
HongKong:1801
OTC-PINK:IVBIY
Summary
Key Points: 
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.


Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, Nov. 27, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), olverembatinib (BCL-ABL TIK), IBI188(anti-CD47 monoclonal antibody), IBI110 (anti-LAG-3 monoclonal antibody) and IBI939 (anti-TIGIT monoclonal antibody) will be presented at the upcoming international medical conferences. A brief summary of the presentations is as follows:

EUROPEAN SOCIETY OF MEDICAL ONCOLOGY IMMUNO-ONCOLOGY CONGRESS 2022 (Dec 7-9)

Topic: Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in advanced squamous non-small cell lung cancer (sqNSCLC): updated results of the Phase Ib study
Presentation Type: Poster
Poster Number: 86P
Main Researchers: Professor Caicun Zhou, Shanghai Pulmonary Hospital; Professor Nong Xu, The First Affiliated Hospital, School of Medicine, Zhejiang University.

Topic: A Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC)
Presentation Type: Poster
Poster Number: 77P
Main Researcher: Professor Ying Cheng, Jilin Cancer Hospital.

64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING & EXPOSITION (Dec 10-13)

Topic: A phase 1b study to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome
Presentation Type: Poster
Poster Number: 1759
Main Researchers: Professor Zhijian Xiao, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Professor Miao Miao, The First Affiliated Hospital of Suzhou University.

Topic: Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
Presentation Type: Oral Presentation
Abstract Number: 170698
Main Researcher: Professor Qian Jiang, Peking University Institute of Hematology, Peking University People's Hospital.

Topic: A Five-Year Follow-up on Safety and Efficacy of Olverembatinib  (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI）, in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China with T315I Mutation
Presentation Type: Oral Presentation
Abstract Number: 170868
Main Researcher: Professor Qian Jiang, Peking University Institute of Hematology, Peking University People's Hospital.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune disease, metabolic disorder and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 35 valuable assets in the fields of cancer, metabolic disorder, autoimmune disease and other major therapeutic areas, with 8 approved products on the market. These include: TYVYT® (sintilimab injection), BYVASDA®(bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA®(rituximab biosimilar injection), Pemazyre®(pemigatinib oral inhibitor), olverembatinib (BCR-ABL TKI), Cyramza® (ramucirumab) and selpercatinib. An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies.

Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com. and www.linkedin.com/company/innovent-biologics/.

Note:

TYVYT® (sintilimab injection) is not an approved product in the United States.

BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.

TYVYT® (sintilimab injection, Innovent)

BYVASDA® (bevacizumab biosimilar injection, Innovent)

HALPRYZA® (rituximab biosimilar injection, Innovent)

SULINNO® (adalimumab biosimilar injection, Innovent)

Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.

CYRAMZA® (ramucirumab, Eli Lilly). CYRAMZA® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.

Selpercatinib (Eli Lilly). Selpercatinib was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.

Disclaimer:
1. The indications are still under clinical study, which haven't been approved in China.
2. Innovent does not recommend any off-label usage.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

Cision View original content:https://www.prnewswire.com/news-releases/innovent-announced-clinical-data-of-multiple-trials-will-be-presented-at-the-2022-esmo-io-and-ash-annual-meetings-301687463.html

SOURCE Innovent Biologics

Copyright: 
2022 PR Newswire. All Rights Reserved.